PMID- 31868204 OWN - NLM STAT- MEDLINE DCOM- 20210316 LR - 20210316 IS - 1573-4935 (Electronic) IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 40 IP - 1 DP - 2020 Jan 31 TI - MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. LID - 10.1042/BSR20191234 [doi] LID - BSR20191234 AB - AIM: Circulating microRNA expression has become a biomarker of cardiovascular disease; however, the association of microRNA expression between circulation and myocardium in hypertrophic cardiomyopathy remains unclear. The present study aimed to find a circulating biomarker correlated not only to myocardial expression, but also to cardiac hypertrophy and fibrosis. METHOD: Forty-two cases of hypertrophic obstructive cardiomyopathy (HOCM) diagnosed by echocardiography and magnetic resonance were analysed for microRNA expression in plasma and myocardial tissue. RESULTS: The results showed that myocardial miR-221 was significantly increased (z = -2.249, P = 0.024) and significantly correlated with collagen volume fraction (CVF) (r = 0.516, P < 0.001), late gadolinium enhancement (LGE) (r = 0.307, P = 0.048), and peripheral circulation (r = 0.434, P = 0.004). Moreover, circulating miR-221 expression was significantly correlated with CVF (r = 0.454, P = 0.002), LGE (r = 0.630, P = 0.004), maximum interventricular septal thickness (MIVST) of echocardiography (r = 0.318, P = 0.042), and MIVST of magnetic resonance (r = 0.342, P = 0.027). The area under the receiver operating characteristic curve of miR-221 was 0.764. CONCLUSIONS: Circulating miR-221 is consistent with that in myocardial tissue, and correlated with myocardial fibrosis and hypertrophy. It can be used as a biomarker for evaluating myocardial hypertrophy and fibrosis in HOCM. CI - (c) 2020 The Author(s). FAU - Huang, Derong AU - Huang D AD - Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Chen, Zhongxiu AU - Chen Z AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Wang, Jie AU - Wang J AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Chen, Yucheng AU - Chen Y AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Liu, Daxing AU - Liu D AD - Department of Cardiovascular Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563100, China. FAU - Lin, Ke AU - Lin K AD - Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. LA - eng PT - Journal Article PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - 0 (Biomarkers) RN - 0 (Circulating MicroRNA) RN - 0 (MIRN221 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Biomarkers/blood MH - Cardiomyopathy, Hypertrophic/*blood/diagnostic imaging/genetics/pathology MH - Circulating MicroRNA/*blood/genetics MH - Echocardiography MH - Female MH - Fibrosis MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - MicroRNAs/*blood/genetics MH - Middle Aged MH - Myocardium/*metabolism/pathology MH - Predictive Value of Tests MH - Up-Regulation MH - Young Adult PMC - PMC6954366 OTO - NOTNLM OT - MicroRNA OT - hypertrophic obstructive cardiomyopathy OT - myocardial fibrosis OT - myocardial hypertrophy COIS- The authors declare that there are no competing interests associated with the manuscript. EDAT- 2019/12/24 06:00 MHDA- 2021/03/17 06:00 PMCR- 2020/01/10 CRDT- 2019/12/24 06:00 PHST- 2019/05/08 00:00 [received] PHST- 2019/12/16 00:00 [revised] PHST- 2019/12/19 00:00 [accepted] PHST- 2019/12/24 06:00 [pubmed] PHST- 2021/03/17 06:00 [medline] PHST- 2019/12/24 06:00 [entrez] PHST- 2020/01/10 00:00 [pmc-release] AID - 221713 [pii] AID - BSR20191234 [pii] AID - 10.1042/BSR20191234 [doi] PST - ppublish SO - Biosci Rep. 2020 Jan 31;40(1):BSR20191234. doi: 10.1042/BSR20191234.